In the field of theranostics, the use of PSMA for imaging in patients with advanced prostate cancer has led to the incidental detection of extra-prostatic concurrent tumors showing increased uptake of the radiolabeled compound, including sarcomas [17, 18]. The gene discussed is FOLH1; the disease is prostate carcinoma.